基于巨噬细胞调控的慢性胰腺炎免疫治疗研究进展
Research Progress on Macrophage-Mediated Immunotherapy for Chronic Pancreatitis
DOI: 10.12677/acm.2026.1641247, PDF,   
作者: 徐奕敏, 潘 卓, 黄三雄*：湖州师范学院附属第一医院肝胆胰外科，浙江 湖州
关键词: 慢性胰腺炎；巨噬细胞；免疫治疗；Chronic Pancreatitis； Macrophages； Immunotherapy
摘要: 慢性胰腺炎(CP)是一种常见的胰腺疾病，病因复杂，临床上以反复发作的上腹部疼痛和胰腺外分泌功能不全为主要特征。巨噬细胞作为慢性胰腺炎(CP)发病过程中的关键因素，在疾病早期至晚期的典型病理变化中发挥重要作用。在已形成的慢性胰腺炎阶段，巨噬细胞与T淋巴细胞的相互作用可导致免疫失调。同时，巨噬细胞分泌的促炎细胞因子被认为是腺泡–导管化生(ADM)的潜在驱动因素。本文综述了目前已有的针对巨噬细胞的CP免疫疗法，这将有助于解释巨噬细胞在CP中的重要作用，以及它们作为CP免疫治疗靶点的潜力。这些发现有助于提高巨噬细胞在慢性胰腺炎治疗中的靶向干预效果。
Abstract: Chronic pancreatitis (CP) is a common pancreatic disorder with a complex etiology, clinically characterized by recurrent upper abdominal pain and pancreatic exocrine insufficiency. Macrophages, as critical mediators in the pathogenesis of CP, play essential roles throughout the disease course, from early inflammatory responses to advanced pathological remodeling. During the established stage of CP, interactions between macrophages and T lymphocytes contribute to immune dysregulation. In addition, proinflammatory cytokines secreted by macrophages are considered potential drivers of acinar-to-ductal metaplasia (ADM). This review summarizes current macrophage-targeted immunotherapeutic strategies for CP, aiming to elucidate the pivotal role of macrophages in disease progression and to evaluate their potential as therapeutic targets. These insights may contribute to optimizing macrophage-targeted interventions and improving therapeutic efficacy in the management of chronic pancreatitis.
文章引用：徐奕敏, 潘卓, 黄三雄. 基于巨噬细胞调控的慢性胰腺炎免疫治疗研究进展[J]. 临床医学进展, 2026, 16(4): 256-262. https://doi.org/10.12677/acm.2026.1641247

参考文献

[1] Kleeff, J., Whitcomb, D.C., Shimosegawa, T., Esposito, I., Lerch, M.M., Gress, T., et al. (2017) Chronic Pancreatitis. Nature Reviews Disease Primers, 3, Article No. 17060. [Google Scholar] [CrossRef] [PubMed]
[2] Rawla, P., Sunkara, T. and Gaduputi, V. (2019) Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World Journal of Oncology, 10, 10-27. [Google Scholar] [CrossRef] [PubMed]
[3] Kichler, A. and Jang, S. (2020) Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates. Drugs, 80, 1155-1168. [Google Scholar] [CrossRef] [PubMed]
[4] Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P. and Chen, X. (2020) Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. Advanced Materials, 32, e2002054. [Google Scholar] [CrossRef] [PubMed]
[5] Atri, C., Guerfali, F.Z. and Laouini, D. (2018) Role of Human Macrophage Polarization in Inflammation during Infectious Diseases. International Journal of Molecular Sciences, 19, Article 1801. [Google Scholar] [CrossRef] [PubMed]
[6] Bartel, M., Hänsch, G., Giese, T., Penzel, R., Ceyhan, G., Ketterer, K., et al. (2008) Abnormal Crosstalk between Pancreatic Acini and Macrophages during the Clearance of Apoptotic Cells in Chronic Pancreatitis. The Journal of Pathology, 215, 195-203. [Google Scholar] [CrossRef] [PubMed]
[7] Weber, C. (2015) Alternatively Activated Macrophages Mediate Fibrosis. Nature Reviews Gastroenterology & Hepatology, 12, 372-372. [Google Scholar] [CrossRef] [PubMed]
[8] Schlosser, W., Schlosser, S., Ramadani, M., Gansauge, F., Gansauge, S. and Beger, H. (2002) Cyclooxygenase-2 Is Overexpressed in Chronic Pancreatitis. Pancreas, 25, 26-30. [Google Scholar] [CrossRef] [PubMed]
[9] Koliopanos, A., Friess, H., Kleeff, J., Roggo, A., Zimmermann, A. and Büchler, M.W. (2001) Cyclooxygenase 2 Expression in Chronic Pancreatitis: Correlation with Stage of the Disease and Diabetes Mellitus. Digestion, 64, 240-247. [Google Scholar] [CrossRef] [PubMed]
[10] Haanen, C. (2001) Sulindac and Its Derivatives: A Novel Class of Anticancer Agents. Current Opinion in Investigational Drugs, 2, 677-683.
[11] Bai, H., Chen, X., Zhang, L. and Dou, X. (2012) The Effect of Sulindac, a Non-Steroidal Anti-Inflammatory Drug, Attenuates Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis. BMC Gastroenterology, 12, Article No. 115. [Google Scholar] [CrossRef] [PubMed]
[12] Bombardo, M., Malagola, E., Chen, R., Rudnicka, A., Graf, R. and Sonda, S. (2018) Ibuprofen and Diclofenac Treatments Reduce Proliferation of Pancreatic Acinar Cells Upon Inflammatory Injury and Mitogenic Stimulation. British Journal of Pharmacology, 175, 335-347. [Google Scholar] [CrossRef] [PubMed]
[13] Reding, T., Bimmler, D., Perren, A., Sun, L., Fortunato, F., Storni, F., et al. (2006) A Selective COX-2 Inhibitor Suppresses Chronic Pancreatitis in an Animal Model (WBN/Kob Rats): Significant Reduction of Macrophage Infiltration and Fibrosis. Gut, 55, 1165-1173. [Google Scholar] [CrossRef] [PubMed]
[14] Huang, T., Liu, Y. and Zhang, C. (2019) Pharmacokinetics and Bioavailability Enhancement of Baicalin: A Review. European Journal of Drug Metabolism and Pharmacokinetics, 44, 159-168. [Google Scholar] [CrossRef] [PubMed]
[15] Fan, J., Duan, L., Wu, N., Xu, X., Xin, J., Jiang, S., et al. (2021) Baicalin Ameliorates Pancreatic Fibrosis by Inhibiting the Activation of Pancreatic Stellate Cells in Mice with Chronic Pancreatitis. Frontiers in Pharmacology, 11, Article ID: 607133. [Google Scholar] [CrossRef] [PubMed]
[16] Jin, X.Y., Sohn, D.H. and Lee, S.H. (2016) Isoliquiritigenin Suppresses Tumor Necrosis Factor-α-Induced Inflammation via Peroxisome Proliferator-Activated Receptor-γ in Intestinal Epithelial Cells. Archives of Pharmacal Research, 39, 1465-1471. [Google Scholar] [CrossRef] [PubMed]
[17] Ye, H., Yang, X., Chen, X., Shen, L. and Le, R. (2020) Isoliquiritigenin Protects against Angiotensin II-Induced Fibrogenesis by Inhibiting NF-κB/PPARγ Inflammatory Pathway in Human Tenon’s Capsule Fibroblasts. Experimental Eye Research, 199, 108146. [Google Scholar] [CrossRef] [PubMed]
[18] Chi, J., Seo, G.S., Cheon, J.H. and Lee, S.H. (2017) Isoliquiritigenin Inhibits TNF-α-Induced Release of High-Mobility Group Box 1 through Activation of HDAC in Human Intestinal Epithelial HT-29 Cells. European Journal of Pharmacology, 796, 101-109. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, L., He, L., Hao, L., Guo, H., Zeng, X., Bi, Y., et al. (2020) Isoliquiritigenin Ameliorates Caerulein‐Induced Chronic Pancreatitis by Inhibiting the Activation of PSCs and Pancreatic Infiltration of Macrophages. Journal of Cellular and Molecular Medicine, 24, 9667-9681. [Google Scholar] [CrossRef] [PubMed]
[20] Klieser, E., Swierczynski, S., Mayr, C., Schmidt, J., Neureiter, D., Kiesslich, T., et al. (2015) Role of Histone Deacetylases in Pancreas: Implications for Pathogenesis and Therapy. World Journal of Gastrointestinal Oncology, 7, 473-483. [Google Scholar] [CrossRef] [PubMed]
[21] Grabiec, A.M., Tak, P.P. and Reedquist, K.A. (2011) Function of Histone Deacetylase Inhibitors in Inflammation. Critical Reviews™ in Immunology, 31, 233-263. [Google Scholar] [CrossRef] [PubMed]
[22] Shakespear, M.R., Halili, M.A., Irvine, K.M., Fairlie, D.P. and Sweet, M.J. (2011) Histone Deacetylases as Regulators of Inflammation and Immunity. Trends in Immunology, 32, 335-343. [Google Scholar] [CrossRef] [PubMed]
[23] P, K.M., Sivashanmugam, K., Kandasamy, M., Subbiah, R. and Ravikumar, V. (2021) Repurposing of Histone Deacetylase Inhibitors: A Promising Strategy to Combat Pulmonary Fibrosis Promoted by TGF-β Signalling in COVID-19 Survivors. Life Sciences, 266, Article 118883. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, F., Gao, Q., Wei, A., Chen, X., Shi, Y., Wang, H., et al. (2020) Histone Deacetylase 3 Aberration Inhibits Klotho Transcription and Promotes Renal Fibrosis. Cell Death & Differentiation, 28, 1001-1012. [Google Scholar] [CrossRef] [PubMed]
[25] Huang, L. (2006) Targeting Histone Deacetylases for the Treatment of Cancer and Inflammatory Diseases. Journal of Cellular Physiology, 209, 611-616. [Google Scholar] [CrossRef] [PubMed]
[26] Nencioni, A., Beck, J., Werth, D., Grünebach, F., Patrone, F., Ballestrero, A., et al. (2007) Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity. Clinical Cancer Research, 13, 3933-3941. [Google Scholar] [CrossRef] [PubMed]
[27] Xiao, B., Lu, C. and Link, H. (2007) Cell Biology and Clinical Promise of G‐CSF: Immunomodulation and Neuroprotection. Journal of Cellular and Molecular Medicine, 11, 1272-1290. [Google Scholar] [CrossRef] [PubMed]
[28] Sato, T., Suzuki, H., Kusuyama, T., Omori, Y., Soda, T., Tsunoda, F., et al. (2008) G-CSF after Myocardial Infarction Accelerates Angiogenesis and Reduces Fibrosis in Swine. International Journal of Cardiology, 127, 166-173. [Google Scholar] [CrossRef] [PubMed]
[29] Chang, Y., Zhao, X. and Huang, X. (2019) Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Frontiers in Immunology, 10, Article ID: 2516. [Google Scholar] [CrossRef] [PubMed]
[30] Rahi, V., Jamwal, S. and Kumar, P. (2021) Neuroprotection through G-CSF: Recent Advances and Future Viewpoints. Pharmacological Reports, 73, 372-385. [Google Scholar] [CrossRef] [PubMed]
[31] Lin, W., Brittan, M. and Alison, M.R. (2008) The Role of Bone Marrow-Derived Cells in Fibrosis. Cells Tissues Organs, 188, 178-188. [Google Scholar] [CrossRef] [PubMed]
[32] Rojas, M., Xu, J., Woods, C.R., Mora, A.L., Spears, W., Roman, J., et al. (2005) Bone Marrow-Derived Mesenchymal Stem Cells in Repair of the Injured Lung. American Journal of Respiratory Cell and Molecular Biology, 33, 145-152. [Google Scholar] [CrossRef] [PubMed]
[33] Lin, W., Yen, T., Lim, S., Perng, M., Lin, C., Su, M., et al. (2014) Granulocyte Colony-Stimulating Factor Reduces Fibrosis in a Mouse Model of Chronic Pancreatitis. PLOS ONE, 9, e116229. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, H., Shan, Y., Wu, Y., Xu, C., Yu, X., Zhao, J., et al. (2017) Berberine Suppresses LPS-Induced Inflammation through Modulating SIRT1/NF-κB Signaling Pathway in RAW264.7 Cells. International Immunopharmacology, 52, 93-100. [Google Scholar] [CrossRef] [PubMed]
[35] Wang, K., Feng, X., Chai, L., Cao, S. and Qiu, F. (2017) The Metabolism of Berberine and Its Contribution to the Pharmacological Effects. Drug Metabolism Reviews, 49, 139-157. [Google Scholar] [CrossRef] [PubMed]
[36] Bansod, S., Doijad, N. and Godugu, C. (2020) Berberine Attenuates Severity of Chronic Pancreatitis and Fibrosis via AMPK-Mediated Inhibition of TGF-β1/Smad Signaling and M2 Polarization. Toxicology and Applied Pharmacology, 403, Article 115162. [Google Scholar] [CrossRef] [PubMed]
[37] Lindauer, M. and Hochhaus, A. (2014) Dasatinib. In: Lindauer, M. and Hochhaus, A., Eds., Recent Results in Cancer Research, Springer, 27-65.
[38] O’Brien, S., Berman, E., Borghaei, H., DeAngelo, D.J., Devetten, M.P., Devine, S., et al. (2009) Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network, 7, 984-1023. [Google Scholar] [CrossRef] [PubMed]
[39] Zeng, X., Wang, L., Guo, H., He, L., Bi, Y., Xu, Z., et al. (2019) Dasatinib Ameliorates Chronic Pancreatitis Induced by Caerulein via Anti-Fibrotic and Anti-Inflammatory Mechanism. Pharmacological Research, 147, Article 104357. [Google Scholar] [CrossRef] [PubMed]
[40] Guo, Q. and Qian, Z. (2024) Macrophage Based Drug Delivery: Key Challenges and Strategies. Bioactive Materials, 38, 55-72. [Google Scholar] [CrossRef] [PubMed]
[41] Sarkar, B., Arlauckas, S.P., Cuccarese, M.F., Garris, C.S., Weissleder, R. and Rodell, C.B. (2024) Host-Functionalization of Macrin Nanoparticles to Enable Drug Loading and Control Tumor-Associated Macrophage Phenotype. Frontiers in Immunology, 15, Article ID: 1331480. [Google Scholar] [CrossRef] [PubMed]
[42] Li, Q., Xu, J., Hua, R., Xu, H., Wu, Y. and Cheng, X. (2025) Nano-Strategies for Targeting Tumor-Associated Macrophages in Cancer Immunotherapy. Journal of Cancer, 16, 2261-2274. [Google Scholar] [CrossRef] [PubMed]
[43] Xu, M., Cui, Y., Wei, S., Cong, X., Chen, Y., Tian, S., et al. (2023) Emerging Nanomaterials Targeting Macrophage Adapted to Abnormal Metabolism in Cancer and Atherosclerosis Therapy (Review). International Journal of Molecular Medicine, 53, Article No. 13. [Google Scholar] [CrossRef] [PubMed]

为你推荐